江湖电竞直播网址
VCEL
US
$
0.00
0.00%
After Hours
$
26.02
After Hours Volume:
31.82K
| Close | Chg | Chg % |
|---|---|---|
| $26.02 | 0.77 | 3.05% |
Volume: 232.17K
65 Day Avg: 416.25K
25.48
Day Range
26.27
22.06
52 Week Range
55.20
Overview
VCEL Overview
Key Data
- Open $25.48
- Day Range 25.48 - 26.27
- 52 Week Range 22.06 - 55.20
- Market Cap $1.19B
- Shares Outstanding 47.18M
- Public Float 46.84M
- Beta 1.41
- Rev. per Employee $552.37K
- P/E Ratio N/A
- EPS -$0.36
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 8.03M 08/15/22
- % of Float Shorted 17.15%
- Average Volume 416.25K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings
5
Full Ratings
Recent News
Vericel started at buy with $44 stock price target at Truist
Vericel price target raised to $40 from $30 at Truist Securities, stock rated buy
Vericel started at buy with $24 stock price target at Truist
Vericel started at outperform with $23 stock price target at Oppenheimer
Vericel's stock soars in premarket-leading volume after FDA approval of cartilage repair product
Shares of Vericel Corp. soared 65% in active premarket trade Wednesday, after the company said its treatment for cartilage defects of the knee was approved by the Food and Drug Administration. Volume topped 2.3 million sh...
Vericel's stock rockets 67% in active premarket trade after FDA approves knee cartilage defect treatment
Vericel's stock soars in active trade after positive trial results
Vericel Corp.'s stock rocketed 92% in very active premarket trade Thursday, after the biotechnology company announced positive trial results for its heart failure treatment. Trading volume just before the open was about 7...
The Bull Market Is Still Alive
on InvestorPlace.com
The Bull Market Is Still Alive
on InvestorPlace.com
A Golden Ticket to Beat the Fed and Profit in “Hidden Bull Markets”
on InvestorPlace.com
Looking Into Vericel's Return On Capital Employed
on Benzinga.com
How Much Upside is Left in Vericel Corporation (VCEL)? Wall Street Analysts Think 53%
The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Vericel Corporation (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend i...
on Zacks.com
H.C. Wainwright Sticks to Its Buy Rating for Vericel (VCEL)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Vericel (VCEL – Research Report) yesterday and set a price target of $53.00. The company's shares closed last Thursday at $30.43. According to TipRa...
on TipRanks.com
Vericel (VCEL) Q2 2022 Earnings Call Transcript
on Motley Fool
Analysts Conflicted on These Healthcare Names: Vericel (VCEL), Addus Homecare (ADUS) and Baxter International (BAX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vericel (VCEL – Research Report), Addus Homecare (ADUS – Research Report) and Baxter International (BAX – Research Report). V...
on TipRanks.com
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -46.15% and 3.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
on Zacks.com
Vericel: Q2 Earnings Insights
on Benzinga.com
Top 5 2nd Quarter Trades of Conestoga Capital Advisors, LLC
Top 5 2nd Quarter Trades of Conestoga Capital Advisors, LLC
on GuruFocus.com
Stocks That Hit 52-Week Lows On Tuesday
on Benzinga.com
Vericel Earnings Perspective: Return On Capital Employed
on Benzinga.com
Top 5 1st Quarter Trades of Kent Lake Capital LLC
Top 5 1st Quarter Trades of Kent Lake Capital LLC
on GuruFocus.com
Top 5 1st Quarter Trades of Kopp Family Office, LLC
Top 5 1st Quarter Trades of Kopp Family Office, LLC
on GuruFocus.com
Vericel (VCEL) Q1 2022 Earnings Call Transcript
on Motley Fool
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
on Zacks.com
Vericel: Q1 Earnings Insights
on Benzinga.com
Earnings Scheduled For May 4, 2022
on Benzinga.com
Vericel Corp.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.